

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Re Application of:

Moody, D. J. *et al.*

Application No: 10/563,459

Filed: January 4, 2006

Title: *Process and Intermediate
Compounds Useful in the
Preparation of Statins, Particularly
Atorvastatin*

Art Unit: *Not Yet Assigned*

Examiner: *Not Yet Assigned*

Attorney Docket No.: UDX-004.01

CERTIFICATE OF FIRST-CLASS MAILING

I hereby certify that this "Response to Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US)" is being deposited with the United States Postal Service as First Class Mail, in an envelope addressed to: Mail Stop Missing Parts, ATTN: DO/EO/US, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on July 5, 2006.


Merlin Aubourg

Mail Stop Missing Parts
ATTN: DO/EO/US
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C.
371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)**

Sir:

Enclosed are the following: (1) A copy of the Notification of Missing Requirements Under 35 U.S.C. 371 In The United States Designated/Elected Office (DO/EO/US); (2) Petition for Extension of Time Under 37 CFR 1.136(a) for one month (one original and one copy); (3) an executed Declaration for Utility or Design Application Using an Application Data Sheet; and (4) two executed Power of Attorney and Correspondence Address Indication Forms.

The Notification also requires the submission of a Sequence Listing. However, the Applicants respectfully contend that the application contains no information for which 37 CFR 1.821-1.825 requires the submission of a Sequence Listing. Accordingly, the Applicants respectfully request withdrawal of this requirement.